Evidence map›Paper›PMID 40894910›Full record

ArticleiScience2025

MEK inhibition prevents human skin graft rejection by promoting CD8

Christine Chauveau, Veronique Nerriere-Daguin, Maeva Fourny, Cynthia Fourgeux, Thibaut Larcher, Laurence Delbos, Martin Braud, Lucas Brusselle, Olivia Rousseau, Jeremie Poschmann and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christine ChauveauCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Veronique Nerriere-DaguinCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Maeva FournyCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Cynthia FourgeuxCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Thibaut LarcherINRAE Oniris, PAnTher, APEX, Oniris, Nantes, France.
Laurence DelbosCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Martin BraudCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Lucas BrusselleCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Olivia RousseauCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Jeremie PoschmannCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Julien VerdierChirurgie Plastique Reconstructrice et Esthétique, CHU de Nantes, Nantes, France.
Fabienne HaspotCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Gilles BlanchoCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.
Simon VilleCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, 44000 Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological MEK inhibition might be an innovative approach to complete the immunosuppressive regimen that enables solid organ transplantation. While MEK inhibitors like trametinib are approved in oncology, their immunomodulatory properties remain poorly investigated in the context of organ transplantation, especially in human context. Using a human skin transplantation model in NSG mice reconstituted with third-party human PBMCs, we evaluated the effects of trametinib on graft survival and the human allogeneic immune response. MEK inhibition significantly prolonged graft survival without reducing graft infiltrate, while preserving the human epidermal tissue. Single-cell RNA sequencing of splenic cells revealed that MEK inhibition impaired CD8

Indexed as

Cell biologyImmune responseTranscriptomics

Identifiers

PMID40894910
PMCPMC12397921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.